Key facts
- It has raised $28.0M; the latest was Later Stage VC ($14.3M) in Jan 2026.
- Notable investors include SAIC Capital China, Shandong Finance Group, Peiyang Begonia Fund, Zheshang Innovest Capital Management, Zhongke Yucheng — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Singe-Cell Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Singe-Cell Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Singe-Cell Biotech
Manufacturer of single cell analysis instruments designed to provide better medical treatment for patients. The company focuses on researching single cell metabolism and developing single-cell dimension medical devices and scientific instruments, providing clients to do single-cell functional imaging, sorting, sequencing and culture.
- Sector
- Healthcare
- HQ
- Qingdao, China
- Founded
- 2014
- Website
- singlecellbiotech.com/
- Ownership
- Privately Held (backing)
Singe-Cell Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Singe-Cell Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Singe-Cell Biotech in its N-PORT filings yet. We sweep new filings monthly.